07:15:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaMERK Equities
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2021-05-25 11:51:55
25 May 2021 - The Annual General Meeting of EXACT Therapeutics AS ('EXACT-Tx' or
the 'Company') will be held on 1 June 2021 at 1300hrs CET. Please find attached
the notice of Annual General Meeting with attendance/Proxy, including the Board
of Directors' proposed resolutions for the items listed on the agenda. The
documents are also available at www.exact-tx.com

Due to the COVID-19 situation the Company's office is closed and the Annual
General Meeting will be held by proxy or by submitting votes in advance.
Shareholders who notify the company will be invited to participate in a
Microsoft Teams meeting, but votes need to be cast in advance. The deadline for
receiving proxies or votes is 30 May 2021 at 12:00 CET. The Annual General
Meeting will be efficiently carried through by strictly keeping to the agenda

For further information, please contact: Masha Stromme, Chair of the Board +47
930 22 509, masha_stromme@fastmail.fm

About EXACT Therapeutics AS: EXACT-Tx is a clinical stage Norwegian biotech
company developing a technology platform for targeted therapeutic enhancement -
Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to
ultrasound-mediated, targeted drug enhancement - with the potential to
significantly amplify the clinical utility of a wide range of therapeutic agents
across a multitude of indications including within oncology (chemotherapy,
immunotherapy), infectious diseases, and neurological conditions.